Log In
Print this Print this

vobarilizumab (ALX-0061) (formerly SC ALX-0061, subcutaneous ALX-0061)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionSubcutaneous nanobody against IL-6 receptor (CD126)
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today